for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Germany takes 300 mln eur stake in vaccine developer CureVac

FRANKFURT, June 15 (Reuters) - Germany will take a stake of about 23% in unlisted biotech firm CureVac by backing a 300 million euro ($337 million) capital increase to fund the company’s further development of a COVID-19 vaccine.

The move was agreed with SAP co-founder Dietmar Hopp - who is an early backer and owner of a stake of more than 80% in CureVac - German Economy Minister Peter Altmaier and Hopp said in an online media briefing.

Reuters earlier reported that a state investment had been agreed.

$1 = 0.8896 euros Reporting by Ludwig Burger Editing by Michelle Martin

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up